Lupus & antiphospholipid syndrome
Effect of rituximab on long-term damage acquisition in patients with systemic lupus erythematosus
Authors' conclusion
While patients treated with rituximab initially had higher damage, their rate of damage progression was slower compared with those receiving standard therapies.
Study context
- Population
- Patients with SLE (94.1% female; 45.4% Caucasian)secondary analysis: 111 patients
- Participants
- 380 patients
- Exposure
- Rituximab vs standard immunosuppressive therapies
- Rituximabn = 190
- Controln = 190reference
- Outcome
- Damage assessed by SLICC/ACR DI
Methodological detailsmatched on sex and age of onset
- Matched on sex and age of onset
Main finding
As reported in the abstract
SLICC/ACR DI
Rituximab
1.3
Control
0.9
P = 0.02
Observational data: associations, not effects.
Further findings
Anti-dsDNA antibody titres
P = 0.012
DI progression (secondary analysis)
Mean
| Outcome | Rituximab | Control | P value |
|---|---|---|---|
| SLICC/ACR DI mean (secondary analysis, 111 patients)No statistical difference | 0.4 | 0.6 | P = 0.33 |
Damage Index (DI) progression (secondary analysis)
- Statistically significant difference between the two groups in DI progression
Original publication
Effect of rituximab on long-term damage acquisition in patients with systemic lupus erythematosus. Rheumatology (Oxford). Published 15 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →